Patents by Inventor Zhen Yu Jin
Zhen Yu Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11207448Abstract: Provided is a biodegradable polymer coating stent effective in delaying the damage of physical properties (particularly radial force) of a core structure. The stent includes a core structure of a bioabsorbable material (e.g., Mg), a first coating layer of a first polymer with biodegradability, and a second coating layer of a second polymer with biodegradability, wherein the first coating layer covers the whole surface of the core structure; the second coating layer covers a part or the whole surface of the first coating layer; the first polymer has a glass transition point of lower than 37° C.; and the second polymer has a glass transition point of 47° C. or higher.Type: GrantFiled: May 24, 2018Date of Patent: December 28, 2021Assignees: JAPAN MEDICAL DEVICE TECHNOLOGY CO., LTD., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Makoto Sasaki, Takuro Niidome, Zhen Yu Jin, Shuzo Yamashita
-
Publication number: 20180264180Abstract: Provided is a biodegradable polymer coating stent effective in delaying the damage of physical properties (particularly radial force) of a core structure. The stent includes a core structure of a bioabsorbable material (e.g., Mg), a first coating layer of a first polymer with biodegradability, and a second coating layer of a second polymer with biodegradability, wherein the first coating layer covers the whole surface of the core structure; the second coating layer covers a part or the whole surface of the first coating layer; the first polymer has a glass transition point of lower than 37° C.; and the second polymer has a glass transition point of 47° C. or higher.Type: ApplicationFiled: May 24, 2018Publication date: September 20, 2018Applicants: Japan Medical Device Technology Co., Ltd., National University Corporation Kumamoto UniversityInventors: Makoto SASAKI, Takuro NIIDOME, Zhen Yu JIN, Shuzo YAMASHITA
-
Patent number: 9040111Abstract: A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.Type: GrantFiled: December 28, 2012Date of Patent: May 26, 2015Assignees: JAPAN STENT TECHNOLOGY CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM, TOYO ADVANCED TECHNOLOGIES CO., LTD.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8968392Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.Type: GrantFiled: July 30, 2012Date of Patent: March 3, 2015Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo IwataInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8641756Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: GrantFiled: June 8, 2012Date of Patent: February 4, 2014Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo Iwata Institute for Frontier Medical Sciences, Kyoto UniversityInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Patent number: 8591571Abstract: A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).Type: GrantFiled: August 25, 2011Date of Patent: November 26, 2013Assignee: Japan Stent Technology Co., Ltd.Inventors: Ikuo Omura, Zhen Yu Jin
-
Patent number: 8409272Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: GrantFiled: September 3, 2008Date of Patent: April 2, 2013Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20130018455Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.Type: ApplicationFiled: July 30, 2012Publication date: January 17, 2013Applicants: JAPAN STENT TECHNOLOGY CO., LTD., HIROO IWATA, TOYO ADVANCED TECHNOLOGIES CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEMInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20120310329Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: ApplicationFiled: June 8, 2012Publication date: December 6, 2012Applicants: JAPAN STENT TECHNOLOGY CO., LTD., HIROO IWATA, TOYO ADVANCED TECHNOLOGIES CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEMInventors: Ikuo OMURA, Zhen Yu JIN, Shuzo YAMASHITA, Hiroo IWATA, Akira MOCHIZUKI
-
Publication number: 20110313514Abstract: A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).Type: ApplicationFiled: August 25, 2011Publication date: December 22, 2011Applicant: JAPAN STENT TECHNOLOGY CO., LTD.Inventors: Ikuo Omura, Zhen Yu Jin
-
Publication number: 20100249914Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: ApplicationFiled: June 2, 2010Publication date: September 30, 2010Applicants: HIROO IWATAInventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
-
Publication number: 20100198344Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.Type: ApplicationFiled: September 3, 2008Publication date: August 5, 2010Applicants: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd.Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki